Loading...

Michael Tanaka, MD

Title(s)Clinical Professor, Ucdhs: Hemat & Oncol
SchoolUniversity of California, Davis
Phone916-734-3772
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P, Mack PC. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. PMID: 28736761.
      View in: PubMed
    2. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. PMID: 25091263.
      View in: PubMed
    3. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack PC, Gandara DR, Davies AM. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug; 29(4):680-7. PMID: 20148348.
      View in: PubMed
    4. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. PMID: 19169683.
      View in: PubMed
    5. Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun; 31(3):226-30. PMID: 18525299.
      View in: PubMed
    6. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 01; 26(4):626-32. PMID: 18235122.
      View in: PubMed
    7. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. PMID: 18090584.
      View in: PubMed
    8. Wang H, Ryu J, Gandara D, Bold RJ, Urayama S, Tanaka M, Goldberg Z, Follette D, Narayan S, Lau D. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007 Feb; 2(2):153-7. PMID: 17410032.
      View in: PubMed
    9. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS, Leichman CG, Macdonald JS. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006 Aug 01; 24(22):3542-7. PMID: 16877719.
      View in: PubMed
    10. Whitehead RP, McCoy S, Macdonald JS, Rivkin SE, Neubauer MA, Dakhil SR, Lenz HJ, Tanaka MS, Abbruzzese JL. Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. Invest New Drugs. 2006 Jul; 24(4):335-41. PMID: 16683076.
      View in: PubMed
    11. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. PMID: 15530258.
      View in: PubMed
    12. Wild CA, Wang SE, Gandara DR, Lara PN, Meyers FJ, Tanaka M, Houston J, Lauder J, Lau DH. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):11-6. PMID: 12886868.
      View in: PubMed
    13. Lim N, Lara PN, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003; 21(1):7-13. PMID: 12643004.
      View in: PubMed
    14. Rothenberg ML, Benedetti JK, Macdonald JS, Seay TE, Neubauer MA, George CS, Tanaka MS, Giguere JK, Pruitt BT, Abbruzzese JL. Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann Oncol. 2002 Oct; 13(10):1576-82. PMID: 12377645.
      View in: PubMed
    15. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D. Premedication strategy for weekly paclitaxel. Cancer Invest. 2002; 20(5-6):666-72. PMID: 12197222.
      View in: PubMed
    16. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. PMID: 11251003.
      View in: PubMed
    17. Perez EA, Scudder SA, Meyers FA, Tanaka MS, Paradise C, Gandara DR. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study. J Immunother (1991). 1991 Feb; 10(1):57-62. PMID: 2012799.
      View in: PubMed
    18. Perez EA, Tanaka M, Gandara DR. Conjugated estrogen for platelet dysfunction associated with liver disease. N Engl J Med. 1988 Jun 09; 318(23):1543. PMID: 2835682.
      View in: PubMed
    19. Shaw ST, Macaulay LK, Sun NC, Tanaka MS, Roche PC. Changes of plasminogen activator in human uterine tissue induced by intrauterine contraceptive devices. Contraception. 1983 Feb; 27(2):131-40. PMID: 6682747.
      View in: PubMed
    20. Shaw ST, Macaulay LK, Tanaka MS, Hohman WR, Moyer DL, Sun NC. Plasminogen activator in human uterine tissue--relationship to location of sampling and time in ovarian cycle. Biochem Med. 1980 Oct; 24(2):170-8. PMID: 7192982.
      View in: PubMed